Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Slides:

Advertisements

Similar presentations

Gene Transcription G0G0 G1G1 Priming S G2G2 M Cell Cell Cycle Growth Factors + Growth Factors & Cell Cycle Receptors.

Advertisements

EGFR exon 20 insertion mutations

Defining Epidermal Growth Factor Receptor exon 20 mutant sensitivity to tyrosine kinase inhibition Danny Rayes.

Lung Cancer Tumour Markers

Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP CHEST

Advances in Molecular Biology of Lung Disease

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Fig. 2. High-resolution melting curves for exon 21 of the EGFR gene

Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical.

P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma Kazuya Takamochi, MD, Shiaki Oh, MD,

Christine L.H. Snozek, Dennis J. O'Kane, Alicia Algeciras-Schimnich

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Targeting signal transduction

Activation of Oncogenic Pathways in Idiopathic Pulmonary Fibrosis

Sustaining Proliferative Signaling and Evading Growth Suppressors

Inhibitor of MAP kinase activation blocks colon cancer growth

Chap. 16 Problem 1 Cytokine receptors and RTKs both form functional dimers on binding of ligand. Ligand binding activates cytosolic kinase domains which.

Miriam Marqués, Francisco X. Real European Urology

HER2/HER3 heterodimers in prostate cancer

cMET Exon 14 Skipping: From the Structure to the Clinic

Daniel Morgensztern, MD, Meghan J. Campo, MD, Suzanne E

Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma Darshil J. Shah, MD, MPH, Roxana S. Dronca,

Extracellular Regulation of Apoptosis

Figure 1 A schematic representation of the HER2 signalling pathway

Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung.

Figure 2 Oestrogen receptor signalling pathways

Nat. Rev. Urol. doi: /nrurol

Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer Roberto Ferrara, MD, Nathalie Auger, MD, Edouard Auclin,

Schematic representation of main EGFR-TKIs resistance mechanisms.

Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer Vassiliki Papadimitrakopoulou,

Schematic view of Trk receptors signalling, showing the three major pathways involved in cell differentiation and survival. Schematic view of Trk receptors.

EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?

A genome-based strategy uncovers frequent BRAF mutations in melanoma

Inflammation, Epithelial to Mesenchymal Transition, and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance Kostyantyn Krysan, PhD,

Apoptosis-targeted therapies for cancer

A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin

Janus Kinase Deregulation in Leukemia and Lymphoma

Nat. Rev. Urol. doi: /nrurol

BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer

Vascular Endothelial Growth Factor (VEGF) Pathway

FGFR Signaling as a Target for Lung Cancer Therapy

Detection rate for EGFR mutations in cfDNA.

Met as a therapeutic target in HCC: Facts and hopes

Clinical courses of patients.

Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer Thomas Winder, Heinz–Josef.

The RAS/MAPK Axis Gets Stressed Out

Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench Kenichi Suda, MD, PhD, Paul A. Bunn,

Christine L.H. Snozek, Dennis J. O'Kane, Alicia Algeciras-Schimnich

RAS and PD-L1: A Masters’ Liaison in Cancer Immune Evasion

Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung.

Molecular mechanisms of IgE regulation

SRC and STAT Pathways Journal of Thoracic Oncology

SOCS Proteins, Regulators of Intracellular Signaling

Yan Feng, MD, Praveena S. Thiagarajan, PhD, Patrick C. Ma, MD

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Apoptosis-targeted therapies for cancer

Masaru Katoh Journal of Investigative Dermatology

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

Simon Ekman, MD, PhD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD

Platelet-derived growth factor (PDGF) signalling pathway.

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

Jinhua Tang, Na Liu, Shougang Zhuang Kidney International

GPC5 Gene and Its Related Pathways in Lung Cancer

Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer Charles M.

The mitogen-activated protein kinase (MAPK) pathway showing mutations identified in pulmonary Langerhans cell histiocytosis (PLCH). The mitogen-activated.

Discovery of a Secreted Tumor Suppressor Provides a Promising Therapeutic Strategy for Follicular Lymphoma Marc R. Mansour, A. Thomas Look Cancer Cell

Simplified BRAF signaling network.

Patterns of clinical relapse and algorithm for the therapeutic strategy when AR to EGFR TKI occurs in patients with EGFR-mutant NSCLC. *After discussion.

Presentation transcript:

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation-positive patients Monic Roengvoraphoj, Gregory J. Tsongalis, Konstantin H. Dragnev, James R. Rigas Cancer Treatment Reviews Volume 39, Issue 8, Pages 839-850 (December 2013) DOI: 10.1016/j.ctrv.2013.05.001 Copyright © 2013 The Authors Terms and Conditions

Fig. 1 The EGFR signaling pathway. Upon ligand binding, EGFR or another ErbB family member dimerizes and is activated through phosphorylation of its intracellular tyrosine kinase domain. This leads to signal transduction through several downstream pathways that regulate apoptosis and cell proliferation. Abbreviations: EGFR, epidermal growth factor receptor; ErbB, erythroblastic leukemia viral oncogene homolog; PI3K, phosphoinositide-3-kinase; AKT, protein kinase B; RAS, retrovirus-associated DNA sequences; RAF, v-raf 1 murine leukemia viral oncogene homolog 1; MEK, mitogen-activated protein kinase kinase; MAPK, mitogen-activated protein kinase; JAK, Janus tyrosine kinase; STAT, signal transducers and activators of transcription. Cancer Treatment Reviews 2013 39, 839-850DOI: (10.1016/j.ctrv.2013.05.001) Copyright © 2013 The Authors Terms and Conditions

Fig. 2 Frequency of mutations in exons 18–21 of the EGFR gene and the association with responsiveness to EGFR TKIs. Diagram depicting the locations and frequencies of EGFR gene mutations detected in the tumors of patients with NSCLC. The most common EGFR mutations are exon 19 deletions and exon 21 point mutations at codon 858, which together account for approximately 80–90% of cases. Reprinted with permission from Macmillan Publishers Ltd: Modern Pathology,30 © 2012. Abbreviations: EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; NSCLC, non-small cell lung cancer. Cancer Treatment Reviews 2013 39, 839-850DOI: (10.1016/j.ctrv.2013.05.001) Copyright © 2013 The Authors Terms and Conditions